drugset / Trial / NCT02493530
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, open-label, study of TGR-1202, a PI3K delta inhibitor, administered together with ruxolitinib in patients with myeloproliferative neoplasms (specifically: polycythemia vera, primary myelofibrosis, PPV-MF or PET-MF) and MDS/MPN.
Timeline
- Start
- 2015-07
- Primary completion
- 2023-03-21
- Completion
- 2024-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | — | — |
| Subject | Umbralisib | Small molecule | — | — |